Clinical trial to evaluate efficacy and safety of low molecular collagen peptides for joint pai
- Conditions
- Diseases of the musculoskeletal system and connective tissue
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 78
(1) Adult men and women aged 40 years or older and less than 75 years old for more than 6 months after being diagnosed with knee arthritis
(2) Those whose Kellgren-Lawrence grading scale of one or both knee joints is grade I or II in simple radiographic examination
(3) Those who have knee arthritis pain score of 30 mm or more evaluated by the Visual analog scale (VAS-100 mm)
(4) Those with a body mass index (BMI) of less than 30 kg/m2
(1) Those who have been diagnosed with inflammatory arthritis such as rheumatoid arthritis or lupus arthritis, or have been diagnosed with secondary osteoarthritis due to systemic disease, etc.
(2) Those with gout, recurrent pseudogout
(3) Those who have infection or severe inflammation of the knee joint, such as septic arthritis
(4) If there is a lower extremity fracture within the last 3 months
(5) Persons with a history of clinically significant hypersensitivity to collagen components
(6) Those who cannot stop taking drugs or health functional foods that affect knee joint pain during the test period from 2 weeks before the first intake of food for human application testing
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Western Ontario and McMaster Universities (WOMAC) pain score after 12 weeks from baseline
- Secondary Outcome Measures
Name Time Method Changes in VAS (Visual Analogue Scale) after 6 weeks and 12 weeks from baseline;Change in WOMAC pain score after 6 weeks from baseline